People · Operator
Named in public records as an officer, director or promoter · active 2013–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CytoSite BioPharma Inc. | — | Biotechnology | Series A | $7.1M | $92.2M | 2019 |
| Sabik Medical Inc. | — | Biotechnology | Seed | $3.0M | $44.3M | 2013 |
Stephen Sands at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Sands on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Jenson | 2 | 3 |
| Richard Smith | 1 | 11 |
| Robert Gailus | 1 | 4 |
| Eric Evans | 1 | 3 |
| Allan Green | 1 | 2 |
| Daniel Peters | 1 | 2 |
| Ellen Cordo | 1 | 1 |
| Howard Fillit | 1 | 1 |
| Daniel L. Peters | 1 | 1 |
| Ray Dunn | 1 | 1 |
| Mark Mintun | 1 | 1 |
| Michel Chu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.